Supernus Pharmaceuticals (SUPN) Long-Term Investments (2012 - 2024)

Supernus Pharmaceuticals (SUPN) has 13 years of Long-Term Investments data on file, last reported at $11.7 million in Q1 2024.

• Long-Term Investments for Q1 2024 came in at $11.7 million, down 78.47% year-over-year; the trailing twelve-month figure through Mar 2024 was $11.7 million (down 78.47% YoY), and the FY2023 annual result was $16.6 million, down 82.3% from the prior year.
• Long-Term Investments eased to $11.7 million in Q1 2024 per SUPN's latest filing, from $16.6 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $534.7 million in Q1 2020 and troughed at $11.7 million in Q1 2024.
• A 5-year average of $215.4 million and a median of $131.9 million in 2022 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2023: Long-Term Investments grew 24.2% in 2021, then tumbled 82.3% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $350.4 million in 2020, then sank by 65.99% to $119.2 million in 2021, then declined by 21.21% to $93.9 million in 2022, then plunged by 82.3% to $16.6 million in 2023, then decreased by 29.82% to $11.7 million in 2024.
• Business Quant data shows SUPN's Long-Term Investments at $11.7 million in Q1 2024, $16.6 million in Q4 2023, and $25.1 million in Q3 2023.